annuel report 2010

2010 ANNUAL REPORT

ContentsINTERVIEW P. 02

OUR PROFILE P. 04 • Who are we?• Our employees• Highlights• Corporate governance

OUR 3 MISSIONS P. 14 • Research• Care• Teaching

OUR RESOURCES P. 32

GLOSSARY P. 40

Institut Curie is a private foundation granted charitable status in 1921. Founded in 1909 on a model developed by Marie Curie that is still germane today - “from fundamental research to innovative patient care”, Institut Curie's missions are research, care, and teaching to assist patients with cancer.

Communications Department — July 2011 — Photo credits: Noak / Le Bar Floréal - Pedro Lombardi - Eric Bouvet - Christophe Hargoues - Marie-Ange Deugnier - Michel Brisset - Franck Perez - Arnaud Echard / Institut Curie — Design and publishing : All Contents — Fabrication : tcgraphite — Printed with vegetable-based inks on paper from sustainably managed forests meeting environmental standards.

2010 Annual Report

Institut Curie — 2010 Annual Report 32 Institut Curie — 2010 Annual Report

Interview

Prof. Claude Huriet “We can all take action.”

Has Institut Curie been affected by the global economic crisis?The economic environment is challenging, but Institut Curie has been spared to a great degree due to the diversity of our funding sources. Donors have continued to demonstrate their generosity. France’s policy of boosting research in the country, coupled with innovative projects that researchers have presented, have led to the State’s continued support. We must pursue these efforts, because the new funding rules for hos-pitals are quite restrictive. We’re worried about the economic situation and, like all organizations and companies, Institut Curie is vulnerable. We saw an increase (+9%) of our total resources in 2010, but also an increase in our operating expenses (+7%). To continue leading the fi ght against cancer, we need more state support, along with that of our donors and sponsors.

What are the more exceptional dimensions of the 2010 budget, in your opinion?Our activities growth means mobilizing on a broad scale to ensure

continued fi nancing for our projects. So it’s essential that we continue working in Networks of Excellence, such as those stimulating innovation, promoted by the French National Loan. Research activities have experienced extraordinary growth, fed by a very strong increase in resources from research contracts (+45%) and fairly signifi cant growth in public donations. However, the volume in-crease seen in patient care activities was not suffi cient to offset the decrease in resources from health insurance and investment so as to update our hospital facilities.

Are there any 2010 highlights you’d like to mention?Yes, at least two! Integrating the René Huguenin Hospital in Saint-Cloud (Paris region) along with its activities and staff, was something to which we committed a great deal of energy. It means we become a major player in oncology, a leader in Europe.And opening the new Proton Therapy Center in Orsay (Paris region) has been a matter of pride for us, because it provides patients with innovative technology and highly humanized care, letting us treat a greater number of cancer patients, especially children.

What are your conclusions now that the year is over?First, I’d like to thank all those who make Institut Curie everything that it is. I’m thinking especially of our 3,037 employees in all their differ-ent responsibilities and departments. Their commitment and sense of belonging surpass all quantitative concepts – it’s the qualitative dimen-sion of their work that makes us an institution of such international renown. And now, as we’re getting ready to celebrate the centenary of the second Nobel Prize awarded to our founder, Marie Curie, I am proud of all that our teamwork has accomplished.

What is the vision for Institut Curie in the coming years?Institut Curie will be going even further with the foundation’s missions: patient care, research, and knowledge transfer. Our values of humanity, effi cacy, innovation, openness, and a sense of sharing will help us. We will particularly continue to invest in developing translational research, as well as in our work supporting comprehensive, individualized care for each patient, while improving our facilities to provide the needed support to those affected by cancer.

In 2010, Institut Curie became the embodiment of the word “unite” more than ever before. The institute, a private charitable foundation, relied on the united force of diverse resources for its funding. Also, the foundation’s know-how and skills in the fi ght against cancer were enriched with some seven hundred employees uniting with the present Institut Personnel. An interview with Professor Claude Huriet, President of Institut Curie.

unite More than 3,000 employees

187,000 donators

+ 9% in resources

Ourprofi le

A community of employees serving patients’ needs


Nearly 102,000 m2 More than € 300 million

« Our strength lies in the close ties cultivated between research and care. »

The institute’s activity is founded on an original model conceived by Marie Curie in 1909.

Institut Curie is a private charitable foundation whose mission is to develop research, care for cancer patients, and teaching.

provide patients with the benefi ts of the most recent advances.In the area of care, Institut Curie is considered centre de référence* for breast cancer and pediatric and ocular tumors. Caregivers, who are at the forefront of the overall care given to patients at all stages of the disease, have the latest systems of reference and the best technologies available to them to improve their patients’ treatments and quality of life.Lastly, teaching and training is an institutional priority for Institut Curie. By being an infl uential element in the dissemination of knowledge, Institut Curie contributes to advancing know-how in the fi eld and improving patient care.

research with public organizations – CNRS, Inserm, universities – and private companies, including pharmaceutical laboratories.

Three complementary missionsUnderstanding the complex working of the normal or cancerous cell to explore ground-breaking therapeutic avenues that are ever more

of hospitals and research laboratories in Paris and in Orsay, and Saint-Cloud (Paris region)

of total budget in 2010, including 9% from public donations

effective is the mission of the Research Center. This center brings together a number of multidisciplinary teams and provides them with advanced technology platforms. To facilitate the transfer of research laboratory discoveries to bedside applications for the patient, translational research counts on the skills of a team made up of both researchers and doctors to more effi ciently

With innovation as its focus, the foundation encourages close collaboration between basic research and innovative care, all to the benefi t of its patients. In keeping with this objective, 4 new programs funded by public donations were initiated in 2010 on cell division, screening, micrometastasis, and retinoblastoma.More than 3,000 employees – researchers, caregivers, and technical, administrative, and support staff – are committed to assisting the institute in the fi ght against cancer.As a leading player among those in the public and private sectors involved in the fi ght against these diseases, Institut Curie has developed numerous partnerships in basic or applied

Meeting the challenges of cancer treatmentIn its desire to best meet the cancer challenges of the 21st century, Institut Curie has established several objectives:• to enhance the cross-

disciplinarity between researchers and caregivers to help them achieve a high level of excellence;

• to promote basic research in cancer development mechanisms;

• to be nationally and internationally recognized as the leading “integrated site for research in the fi ght against cancer”;

• to enhance training and postgraduate teaching;

• to share the institute’s know-how and medical

innovations;• to develop the prestige and

infl uence of the institute’s intellectual property and industrial partnerships;

• to increase national and international cooperative undertakings.

* In order to structure patient care in France, the country’s health regulatory bodies have offi cially named certain centers of expertise “centres de référence” or model centers.

Who are we?

Combining the leading French cancer research center and a state-of-the-art hospital group in oncology, Institut Curie is an institution devoted to research, care, and teaching.

Institut Curie,today and tomorrow

The mergerThe merger between Institut Curie and the René Huguenin Center, a center devoted to the fi ght against cancer (CLCC), which came into effect on January 1st, 2010, is the result of a broad medical and scientifi c project. With the René Huguenin Hospital (Saint-Cloud) and the Hospital at the Paris-Orsay site, Institut Curie now intends to expand staff capabilities in patient care and expedite therapeutic innovation so as to better meet the challenges of cancer research and treatment.


“We want to foster collaboration between physicians and researchers.”

As an institution fi rmly committed to cross-disciplinarity, Institut Curie brings

together multiple skills having a complementary nature that serves as a source of innovation and excellence.

70 nationalities

represented at Institut Curie

Over 100 industrial collaborationcontracts underway, including in clinical research

state-of-the-art technical facilities for patient care. The new Hospital Group, now comprising two hospitals in three locations - Paris, Orsay, and Saint-Cloud –, is pursuing a group project, development of which solicited the teams' in-depth involvement in 2010. Quality care, diversifi ed medical activities, reinforced clinical research, knowledge exchange…the Hospital Group is preparing to collectively face the latest cancer treatment challenges.

Nearly 900 staff in an interdisciplinary research environmentInstitut Curie’s Research Center, a European leader in cancer research, is founded on a multidisciplinary approach

Whether caregivers, researchers, or management professionals, whether working in technical support or logistics, the 3,037 Institut Curie employees are a true community working every day in the fi ght against cancer. This dynamic commitment was exemplifi ed by the publication of some 600 scientifi c and medical articles in top international journals and industrial collaboration contracts.The coexistence of research laboratories and hospital services within a single structure markedly fosters innovation, for it encourages collaboration between caregivers and scientists. Les 7e Journées scientifi ques et médicales de l’Institut Curie, an annual gathering uniting Institut Curie

Distribution of the 3,037 staffinvolving biologists, chemists, physicists, computational biologists, and physicians. Eager to encourage innovation, the center welcomes the best French and foreign talent in an atmosphere highly conducive to creativity and excellence, where these leading-edge minds have access to increasingly sophisticated equipment, particularly in scientifi c imaging. Women hold an important place here, for, out of the 15 research units, seven are managed or co-managed by women, not with some gender-equality goal in mind, but entirely due to their tremendous scientifi c profi ciency.

employees in science and medicine, once again generated a wealth of dialog and shared insights.

More than 2,000 care experts directly benefi ting patientsThe René Huguenin Hospital in Saint-Cloud has been a part

of Institut Curie since January 1st, 2010. By broadening the scope of intervention in hospital operations, this merger strengthens the dynamics at Institut Curie, particularly as a result of a signifi cant increase in the number of patients and employees dedicated to care and a pooling of resources and

Our employees

The rewardsof commitmentThe CNRS bronze medal, the Trophée Femme Santé et Recherche, the Fondation Pierre-Gilles de Gennes award, election to the Académie nationale de pharmacie, appointments to the National Order of the Legion of Honor or Merit, the Gallet & Breton prize of the French Academy of Medicine, the Arc’s Helen-Starck award, the Schlumberger Foundation’s Teaching and Research Award, “best hospital” awards from the press...as in past years, 2010 was studded with numerous awards and honors given to Institut Curie employees, refl ecting the quality of their work and their commitment.

Guided by values of humanity, effi cacy, innovation, sharing and openness, the employees of Institut Curie work daily toward a common goal: providing cancer patients with the best comprehensive care, from diagnosis to monitoring, from patient support to treatment.

Institutional services 48 – 1.6%

Hospital Group 2,023 – 66.6%

Research Center 966 – 31.8%

Highlights

New research teams, improved equipment, signed partnerships... innovation was the focus of 2010. The year was also marked by a strengthening of the breadth of Institut Curie’s hospital structure.

January 1st

The merger between Institut Curie and the René Huguenin Center in Saint-Cloud (Paris region), a center devoted to the fi ght against cancer, or CLCC , took effect on January 1st of this year. The merger will allow better coordination of cancer treatment between the two Paris Region CLCCs. It adds a new dimension to the Hospital Group, which is strengthening its efforts to improve the quality of care for patients and development of clinical research. The group is also becoming European reference center for breast cancer.

May 26th The René Huguenin Hospital unveils its new, latest-generation PET scanner. Using dynamic imaging, this cutting-edge equipment can detect tumors as small as 2mm. It has outstanding image quality and the further advantage of reducing the radiation dose received by the patient. It is faster and more comfortable, paving the way to the study of new mechanisms involved in tumors.

January 1st

Three new research units were established at Institut Curie, after approval from the Evaluation Agency for Research and Higher Education (AERES) and the advisory bodies of Institut Curie’s Research Center, the CNRS, and the Inserm. Bringing the number of research units making up the Research Center to 15, the most recent of which are based in Orsay (Paris region), units focused on understanding molecular mechanisms and oncogenesis, as well as the study of the mechanisms used by the cell to restore genome integrity.

June 10th

The Irène Joliot-Curie Family Center celebrated its 20th anniversary. The location opened in January 1990, serving primarily as accommodation for parents whose children are undergoing treatment or supervision by the Pediatrics Department at Institut Curie. The Family Center also provides parents who have an ill child the comfort, resources, and opportunity to share with others that they often need. It is close to the Paris hospital and has hosted more than 5,000 families in the last 20 years.

March 9th Institut Curie strengthened its industry partnerships, including with the Roche laboratory. A three-year research partnership was signed to explore a new therapeutic molecule developed by Roche that would treat some forms of breast cancer for which current treatments are mostly ineffective. The agreement facilitates a pooling of skills and resources.

December 9th The new Proton Therapy Center at Institut Curie opened at Orsay (Essonne) after a full renovation that took nearly four years. The new facilities make it possible to receive more patients for radiotherapy to treat tumors located near sensitive organs. This center, particularly suited to addressing pediatric cancers, can now treat up to 120 children each year. With this new center, Institut Curie’s radiotherapy technical platform is now one of the largest in Europe.

550 patients, including 120 children,

can now be treated each year at the new Proton Therapy Center

1 2 5 7

6

4

3 8


Corporate governance

Founding members

L’Académie de Paris

L’Institut Pasteur

Prof. Pierre Joliot

Prof. Jean Coursaget

Gérard Wormser

Daniel ThierryTreasurer

Ex offi cio members

The Minister of Health or a representative thereof

The Minister of Education

The Minister of Research

The Minister of Interior

The Mayor of Paris

The President of the Centre National de la Recherche Scientifi que (CNRS)

The CEO of the Institut national de la santé et de la recherche médicale (Inserm)

The Director Generalof the Caisse régionale d’Assurance Maladie d’Île-de-France

The Board of Directors on publication date

The members of Institut Curie's Board of Directors have a wide range of skills and come from a variety of backgrounds, guaranteeing the independence and ethical nature of the institute's strategic choices and the rigor of its management procedures (particularly the approval of the foundation's budget and annual accounts). The President, Prof. Claude Huriet, was reelected in 2007 for another six-year term of offi ce.

Institut Curie's governance is overseen by a Board of Directors,which ensures compliance with the institute's charitable objectives, and a Scientifi c Advisory Board providing guidance on scientifi c strategy.

Qualifi ed members

Prof. Djillali AnnaneDoyen de la Faculté de médecine de l’université Versailles

Prof. Patrick BercheDoyen de la Faculté de médecine Paris Descartes

Jean-Marc BruelMember of the Executive Comittee of the Board

Jean CastexMember of the Executive Comittee of the Board

Prof. Laurent DegosVice President

Jean Gandois

André Gauron Member of the Executive Comittee of the Board

Prof. Claude Huriet President

Prof. François SigauxVice President

President

3 Prof. Iain MattajDirector general of EMBL, Heidelberg (Germany)

Vice President

8 Prof. Ian F. TannokProfessor of Medical Oncology and Medical Biophysics - Ontario Cancer Institute / Princess Margaret Hospital - Toronto - Ontario (Canada)

The Scientifi c Advisory Board on publication date

Comprised of internationally renowned researchers running major foreign research institutions outside Institut Curie, the Scientifi c Advisory Board provides strategic guidance to the Board of Directors regarding the foundation's key priorities and activities. Its President, Prof. Iain Mattaj, was elected in 2010 for a two-year term of offi ce.

Hospital Group representatives

Dr Alain FourquetHead of the Radiotherapy Department

Dr Alain LivartowskiHead of the Medical Information Service

Dr Frédérique SpyratosOncogenetics laboratory

Research Center representatives

Michel BornensCNRS, Molecular Mechanisms of Intracellular Transport Group

Vincent FavaudonInserm, Genotoxicology, Signalization and Experimental Radiotherapy Group

Cécile Sykes CNRS, Group leader of the Biomimetism of Cellular Movement Group

Members

2 Prof. Thierry Boon-FalleurProfessor of Immunology, Ludwig Institute for Cancer Research (Belgium)

4 Prof. Denis DubouleProfessor of Genetics, Director of the Department of Genetics and Evolution - University of Geneva, Federal Institute of Technology, Lausanne (Switzerland)

Prof. Tyler JacksProfessor of Biology, Director, Institute for Integrative Cancer Research at MIT, Cambridge (USA)

Prof. Stanley B. KayeProfessor of Medical Oncology, Medical Section Director, Institute of Cancer Research, Sutton (UK)

5 Prof. Nicole Le DouarinProfesseur honoraire au Collège de France. Secrétaire perpétuel de l’Académie des Sciences, Paris (France)

7 Prof. Paul NursePresident of the Royal Society, London (UK)

1 Prof. James SpudichDepartment of Biochemistry and Developmental Biology, Stanford (USA)

6 Prof. Marc Van de VijverProfessor of Pathology, Head of Department of Pathology,The Netherlands Cancer Institute, Amsterdam (The Netherlands)

Research, Care, Teaching Our3 missions


Research

Exploring new ground to move cancer research forward

Advance our understanding of the mechanisms of cell functioning, improve our knowledge of carcinogenesis, move forward in cancer prevention, diagnosis, and treatment: these are the objectives of the researchers and caregivers at Institut Curie, an institution driven by the need to innovate.

research


Fundamental and translational research

“We assemble many different skills around a common objective.”

One of the largest cancerresearch centers in Europe

A European leader in cancer research, the Research Center at Institut Curie

assembles expertise in a number of different disciplines around a common objective: attaining greater understanding for better treatment.

innovation and bring together the human and material conditions most conducive to new discoveries.This means the Research Center provides the scientifi c community with platforms using advanced techniques: DNA sequencing (genomics), mass spectrometry (proteomics), in vivo experiments, bioinformatics, and a chemolibrary. Here, too, the scientifi c imaging platform is among the best in Europe.In January 2010, Natixis Private Equity and CDC Entreprises, leading players in private equity, launched a venture capital fund, Kurma Biofund, totalling €50 million to fi nance innovative projects initiated by Institut Curie.

Close collaboration with public researchEach of the 84 groups at the Research Center, structured into 15 units, including 3 new units in Orsay (Essonne) in 2010, is the fruit of a close collaboration with public organizations such as CNRS, Inserm, and universities. The units pool expertise and resources around a mutually developed research strategy. Stronger partnerships are therefore being established with universities, including Paris-Descartes (Paris 5) and Paris-Sud (Paris 11) Universities. These agreements demonstrate the common will of Institut Curie and universities to forge solid partnerships in research, teaching, and training through

In 2010, biologists, chemists, physicists, computational biologists, and medical researchers were united in research units with complementary activities structured around nine major areas: cell biology and developmental biology, immunology, genetics and oncogenesis, epigenetics and genotoxicology, medicinal chemistry, physical chemistry of living systems, the molecular mechanisms of oncogenesis, cell and molecular imaging, and bioinformatics.

Technology and know-how to further innovationResearch activities at Institut Curie have traditionally followed the path of excellence and

research, as was done in 2008 with the Pierre and Marie Curie University (UPMC Paris 6).

Facilitate the translation of scientifi c discoveries to medical applicationsThe research performed in the Translational Research Department at Institut Curie, in collaboration with research teams and hospital services, is meant to take new knowledge and translate it as quickly as possible into innovative avenues in the fi eld. This department has the human and technological resources to pursue projects intended to improve patient care. It is also involved in collaborative projects through public and industry partnerships.After a thorough situational

evaluation, this Hospital Group department was restructured within the Research Center on January 1st, 2011. Institut Curie does, indeed, hope to strengthen cross-disciplinarity to help transform the results of cognitive research into advances that can benefi t not only patients undergoing treatment at Institut Curie, but people around the world. This research partnership stance made it possible to sign a three-year agreement with the Roche pharmaceutical company to explore a new therapeutic approach to the more severe forms of breast cancer.

and 50 license agreements to date

in multi-year research contracts in 2010

of fundamental research

in the biotechnology and radiotherapy fi elds

Around 120 patent families

More than €34 million

9 areas

10 spin-off companies created to date


involved in clinical research protocol

conducted at the Hospital Group

invested in 2010 in the “Protected Time” program

Nearly 12% of patients

184 clinical trials

€ 1.4 million

Clinical research

to speed the development of treatments.” “Our research has one clear objective:

• tailoring treatments to the characteristics of each tumor and each patient

• developing research on quality of life and supportive care

The number of patients involved in clinical research protocols conducted by Hospital Group caregivers in 2010 rose to nearly 1,300 patients (nearly 12% of the active patient base).

Dedicated meansTo ensure that innovations springing from research work can become tools in diagnosis or treatment, Institut Curie provides its staff with dedicated resources. The tumor bank is one of these, holding tens of thousands of tumor samples for biological or genetic cancer studies. There is the

Clinical Investigation Unit, as well, for early drug trials, which increased its capacity from 4 hospital beds to 6 in 2010. The Hospital Group was also named one of 16 “early trial centers” in France. This recommendation from the French National Cancer Institute (Inca), part of the 2009-2013 Cancer Plan, seeks to promote performing early clinical trials. Institut Curie has become the leader among centers chosen for testing by the Fédération des centres de lutte contre le cancer (french federation of centers devoted to the fi ght against cancer, or FFCLCC) and the European Organization for Research and Treatment of Cancer (EORTC).

Clinical research relies on the cooperation between caregivers and patients to disseminate the benefi ts of translational and applied research to a wider public. As a result of discoveries in molecular biology, the era of standardized treatment is giving way to individualized patient care, diagnoses, and therapeutic strategies. To achieve this, caregivers perform many clinical trials with patients. Projects at Institut Curie are centered on four key areas:• identifying new drug targets,

developing and evaluating the targeted medications

• developing strategies to reduce treatment side effects, sparing healthy tissues and protecting organs

Human resourcesSo that the hospital teams at Institut Curie are able to spend more time on clinical research, the institute established the “Protected Time” program in 2005. This program, funded by public donations, helps physicians and caregivers set aside time in their daily schedules to conduct or participate in clinical research. Selected through an in-house tender process, 27 doctors, nurses, and medical physicists devoted all or part of their time to applied research projects in 2010, while their patient-care responsibilities were ensured by other professionals during those periods.

For both common cancers and rare cancers, clinical research conducted at Institut Curie helps

generate medical advances. Clinical research is a priority at Institut Curie and depends on a new and unique studies and clinical research commission.


Care

and medical equipment make it all possible.The best skills

Institut Curie places the patient at the center of its activity and has developed a broad spectrum of effective care options, especially involving new therapies, to offer “tailor-made” comprehensive patient care.

react


More than 13,000 patients

Institut Curie’s Hospital Group, a reference center for breast cancer, ocular tumors, and pediatric cancers, is composed

of two hospitals, both centers in the fi ght against cancers (CLCC). Pioneers in many kinds of treatment, they perfected their expertise in innovative care approaches, such as high-precision radiotherapy, nuclear medicine, conservative surgical treatments, and oncogenetics.

now has reduced side effects, which means drugs can be administered on an outpatient basis.This form of outpatient care is also used in radiotherapy and some surgeries, as it signifi cantly improves patients’ quality of life. It limits the

experience of separation many patients encounter – separation from home, family, social and work life – while ensuring the same effective treatment conditions found in full hospitalization.Institut Curie has 69 places for day care, or nearly 20% of

Personalized treatment programsCaregivers work closely together to determine the most appropriate treatment for each patient. To do so, they evaluate their interactions with the patient and ensure comprehensive treatment of all facets of the patient’s experience, including psychological, social, nutritional, functional dimensions, and more.Similarly, surgical procedures preserve the patient’s functional and physical integrity to the greatest degree possible, while respecting the patient’s wishes concerning the intervention.Chemotherapy, used to treat more than half of cancers,

Care

Human expertise to best support our patients

taken care of in 2010

”We put patients and their needs at the center of everything we do.”

the foundation’s total hospitalization capacity. In 2010, nearly 9,000 patients were treated on an outpatient basis at Institut Curie.In radiotherapy, the reopening of the Proton Therapy Center, which also treats outpatients, means that the foundation’s technical resources are some of the most comprehensive in Europe. Caregivers have a broad range of treatment options they can offer in a tailor-made combination to each of their patients. The institute’s international reputation is clearly confirmed by the fact that the 2010 European Breast Cancer Congress (EBCC) was chaired by the Chief of the Cancer Radiotherapy Department at

Institut Curie. The merger of Institut Curie and the René Huguenin Center, the radiotherapy services of three locations – Paris, Orsay, and Saint-Cloud – have been brought together in one department, which pools resources, techniques, and expertise to provide better-coordinated patient care.Hormonal and targeted therapies are also among the medical strategies stemming from recent advances and contributing to improved care.The development of molecular medicine does, indeed, mean that the era of standardized treatment is giving way to truly “tailor-made” individualized therapeutic strategies. Certain new drugs

A center unlike any other in FranceThe new Proton Therapy Center at Institut Curie in Orsay (Paris region) uses a specifi c form of radiotherapy. Proton therapy highly selective radiation treats tumors located near sensitive organs, such as the optic nerve or parts of the brain. It protects the healthier organs nearby and has few side effects. The center’s equipment can now treat new therapeutic indications and more patients, including children.

More than 170,000 consultations

that are developed thus target biological phenomena found in only a handful of patients. Also, early biological analysis of the tumor is at times crucial to choose the most appropriate therapeutic drug for the patient, thus avoiding any inapt treatments.


287 beds

For children and adolescents with cancerous tumors, Institut Curie relies on a

holistic treatment approach too. The various hospital departments involved and the Irène Joliot-Curie Family Center in Paris work in partnership with

common to all centers in the fi ght against cancer (CLCC). National multidisciplinary meetings held to encourage dialog concerning these melanoma give all teams the chance to regularly share their knowledge, so that patients, regardless of where they are

being treated, may benefi t.Medical imaging also saw advancement in May 2010 when a second high-performance PET scanner was installed at the René Huguenin Hospital (Saint-Cloud), ensuring even more precise detection of tumors.

the families, care networks, schooling support, etc. Institut Curie, the main French center for retinoblastoma research and treatment, assists over 80% of newly diagnosed patients each year. With this extensive experience and the support of the Rétinostop association, the institute launched an awareness campaign on retinoblastoma, targeting physicians, in November 2010.In late 2009, Institut Curie was commissioned by the French National Cancer Institute (Inca) to coordinate a national working group on another form of eye cancer: ocular melanoma. This expert panel's task is to establish a database, systems of reference, and protocols

Care

“We want to provide comprehensive, personalized care to every patient.”

Lastly, cross-disciplinary supportive care teams with the responsibility of meeting the needs expressed by the patient or identifying those needs (pain prevention and treatment, psychological support, nutritional and functional assistance, assessment of social concerns, and more) opened a brand-new supportive care offi ce in late 2010 to provide recommendations for case-specifi c physical activities. sOther projects got underway in early 2011, including a comprehensive lymphedema diagnostic bureau as part of the new outpatient support services hospital in Saint-Cloud.

for day care

Quality care makes media headlinesThe hospital reviews and awards conducted and published in 2010 by various consumer magazines provide their own confi rmation of the quality care at Institut Curie hospitals. Among the many ratings and rankings by location or discipline were:- First and 8th places for breast cancer surgery and 9th and 44th places for head and neck cancers in Le Nouvel Observateur’s 2010 national “Hospitals and Clinics” awards;- Second place for breast cancer surgery, 12th place for gynecological cancer care, and 16th place for head and neck cancers in the “2010 Best Hospitals” list by Le Point ;

- A+ (excellent) in the 2010 ratings on pain treatment in hospitals by L’Express;- First and 8th places among the 20 centers in the fi ght against cancer in the 2010 “Safest Hospitals” ranking by L’Express.

69 beds or seats

for conventional hospitalization


Teaching

Actively disseminating knowledge to further research and medicine is an essential part of the public service mission of Institut Curie in the fi ght against cancer.

recognize and share our knowledge with future generations


Institut Curie cultivates knowledge-sharing and does so by organizing high-level courses for graduate and

post-graduate students.

university diplomas) open to physicians. They also lead high-level international and multidisciplinary courses built on the research topics explored by Institut Curie units. Some of these courses are approved as a European university module.Similarly, postgraduate

medical teaching specifi c to cancer studies is provided by Institut Curie caregivers in partnership with universities: university degrees in breast pathology, cancer pharmacology, oncogenetics, and other studies.In 2010, the program supporting physician training in and

Each year, some 400 Master’s and PhD candidates enjoy the benefi ts of a quality scientifi c and medical environment and personalized support.This means that many CNRS and Inserm researchers, physicians, teacher-researchers, and academic-hospital practitioners contribute, through Institut Curie, to courses offered at partner universities at all curriculum levels. Furthermore, in line with Institut Curie’s mission, some of them are involved in graduate and postgraduate education: European Master’s of Genetics; the cellular biology module of the Master’s of the École Normale Supérieure of Paris; Masters, DUs, and DIUs (university and inter-

Teaching

Disseminating knowledgeand skills

following scientifi c curricula

science students

38 Master’s students

171 PhD

“Advancing research and medicine through collaborative projects and disseminating knowledge.”

through research funded a PhD fellowship and two Master’s scholarships for three doctors.

An outstanding international reputationThe scientifi c and medical reputation of Institut Curie has led many PhD students and young post-doctoral or high-level researchers from around the world to seek positions with the institution’s research teams.Each year, some 80 post-doctoral students, more than

for fourth-to sixth-year medical students

in teaching hospitals for physicians undergoing certifi cation

half hailing from other countries, join Institut Curie's laboratories. Since 1997, bridge fi nancing of up to one year has been made available to attract foreign postdoctoral students wanting to conduct their research in an Institut Curie laboratory. For foreign doctorate students, the international doctoral program established in 2005 offers a dozen doctoral grants and mentoring during students’ theses to prepare them for a promising career in science.

Dissemination of knowledgeInstitut Curie keeps the public and its donors informed of progress in research and medicine during national awareness public events, such as the Fête de la Science fair

or European Heritage Days.The institute is also committed to the apprentice-researcher program of the French Association for the Advancement of Science and Research, providing high school students with access to research labs throughout

the school year so as to give them the chance to explore careers in research.From September to June, Institut Curie’s Tuesday conferences provide the public with an opportunity to learn the latest cancer news through dialog with Institut Curie's experts.

117 externships

61 placements

Fostering high-level internationalexchangesEvery year, Institut Curie hosts prestigious scientists of international renown at the Research Center laboratories, thanks to support from the E. de Rothschild and Y. Mayent foundations. These entities furnish grants for sabbaticals, as was the case for several months for Professor Elizabeth H. Blackburn, Professor of Biology and Physiology at the University of California (San Francisco, USA) and 2009 winner of the Nobel Prize in Physiology or Medicine.

The diversity of our funding resources ensures our independence Our resources


Our resources

resourcing The same year also saw 104 new legacy gifts, donations, and life insurance policy contributions to Institut Curie. Here, notaries and fi nancial advisers play an important role as ambassadors for Institut Curie.

Finally, many citizens take part in events held throughout France to benefi t Institut Curie through individual or collective initiatives. For example, the Courir pour la Vie, Courir pour Curie (Run for Life, Run for Curie)

In 2010, Institut Curie received €30.4 million in donations and legacy gifts, 77% of these donations were channeled directly into the foundation’s social missions: cancer research, patient care, and teaching. The remainder was used for institute operations (11%) and to cover fundraising costs (12%).

Every donation countsIn 2010, some 187,000 donors took steps to support Institut Curie, their donations enabling the institution to pursue its mission of conducting research and ensuring cancer patient care. Many donors chose to make monthly donations by setting up a direct-debit gift.

As a registered charity, Institut Curie is authorized to receive donations and legacy

gifts. The generosity of our donors and testators allow us to maintain our fi nancial independence, which is invested in research and innovative care.

Institut Curie is a registered private charitable foundation. It is authorized to receive donations and legacy gifts, and the diversity of its private and public resources acts as a guarantee of the fi nancial independence needed to pursue its public-interest's missions in the fi ght against cancer.

“The trust of our donors is the driving force behind our research.”

Private and public resources*2010 Figures

Friends of Institut CurieMore than 13,000 donors have committed to long-term contributions supporting the work of Institut Curie, choosing to make their donations by direct debit. The regularity of direct-debit donations means that Institut Curie can reduce its costs and plan its activities several years ahead and pursue projects that require signifi cant time and fi nancial resources.

charity run, a long-standing Institut Curie donor, brought 12,149 people out to run in the 2010 event, an athletic and fi nancial challenge that ultimately raised over €84,000.

Businesses support Institut CurieMany fi rms are loyal to Institut Curie’s cause. From corporate sponsorships to investment funds and private sector industrial research contracts, a number of sources contribute to fi nancing the institute’s projects and provide additional resources for researchers and physicians in their goal of developing innovative therapies.

Public fundingThe foundation uses public resources to pursue its public service mission, especially for its healthcare activities, which are fi nanced primarily by health insurance. Furthermore, Institut Curie’s research work is partially funded by research organizations such as CNRS, Inserm, and universities. These entities help fi nance the majority of the payroll and a portion of operating costs and laboratory investments. Institut Curie also receives a grant-in-aid from France’s Ministry of Higher Education and Research. Finally, research teams submit bids to public calls for tender to obtain additional monies.

Use distribution of a €100 donation

€77Social mission

€4 of which is reserved for future undertakings

€11Operating costs

€12Cost of public appeals for donations

€194m61% Health

Insurance

€58m18% Public calls for tender*

€31m10% Other private funding

€29m9% Public generosity

€4m2% Financial products

* including contributions from research organizations, not included in Institut Curie’s annual accounts.

€316m

Expenditure distribution by social mission 2010 fi gures Resource allocation* by social mission 2010 fi gures

TREATMENT ACTIVITIES

Institut Curie’s Hospital Group is an “ESPIC” (Etablissement de santé privé d'intérêt collectif ), or a private, collective-interest healthcare institution. This status means the institute’s primary funding resource is health insurance, which is provided for:• treatment: based on the nature and volume of the treatments provided, with treatments priced on a national level (in a system known as Tarifi cation à l’activité or T2A, for activity-based payment);• contribution to the missions of general interest, including teaching, research, and innovation, on the basis of a block grant (MIGAC) allocated according to performance of each mission.These health insurance revenues are complemented by:• Other revenue from hospital activity (billing of patient care not covered by insurance, user fees, and per diems)• various other revenues (fee supplements for private rooms, for example),• public generosity (donations and legacy gifts) collected by Institut Curie.

RESEARCH

Institut Curie’s Research Center operates in accordance with a very different economic structure than that of the Hospital Group. Activities are developed in partnership with research organizations (CNRS, Inserm, universities). These entities help fi nance the majority of the payroll (researchers, engineers, technicians, and administrative staff), as well as a portion of operating costs and laboratory investments.Institut Curie also receives an annual grant-in-aid from France’s Ministry of Higher Education and Research (MESAR) for its basic research mission. Other resources stem from research contracts, which are most often obtained through national or international tenders. The principal fi nancers are:• public or semi-public: France’s National Research Agency (ANR), France’s

National Cancer Institute (INCA), the Regional Council of Ile de France, the European Research Council (ERC), and the European Commission,

• private: charities that support research (France’s League Against Cancer, Arc, and Medical Research Foundation etc) and industrial fi rms through licensing, collaborations, or partnerships.

These resources are complemented by public donations, which are a vital resource.

TRANSLATIONAL AND CLINICAL RESEARCH ACTIVITIES

Gateway translational, preclinical, and clinical research has developed between the institute’s treatment and basic research activities. The research programs conducted in this context are funded by research contracts or grants that are:• public or semi-public: France’s National Cancer Institute

(INCa), the Regional Council of Ile-de-France etc.• private: industrial companies in collaborative

R&D, licensing, and clinical trials.These resources are complemented by public donations, which are a vital resource.

8%Other hospital resources

87%Health Insurance

5%Other (donations and legacy gifts)

29%Research contracts

40%Contributions from research organizations

15%Public generosity

13%Grant-in-aid from French Department of Education and Research

3%Other

35%Research contracts

47%Public generosity

17%Other revenue

1%Other

Treatment activities 71%

€212.1m

Research 25 %€73.3m

Translational and clinical research activities 4 %€12.8m

Expenditure

The social missions of Institut Curie are centered in a Hospital Group and a Research Center. Each has considerable autonomy, guided by the Board of Directors, and follows a specifi cally tailored economic model. Institut Curie makes great efforts each year to piece together the fi nancial resources necessary to developing and implementing the foundation’s missions.

* Including contributions from research organizations, not included in Institut Curie’s annual accounts.* So as to better compare data, “2009 proforma” includes the René Huguenin Center.

A GROWTH DYNAMICOperating expenses up by 7%**excluding commitments to be achieved.

€261m

€278.9m

2009 proforma *

2010

LOW DEBT

€39m

€259m

2009 proforma *

2009 proforma *

€40m

€257m

2010

2010

Principal still outstanding

Equity

€257.1m

€280.4m

2009 proforma *

2010

Revenue up by 9%**excluding prior funds from previous years carried forward.

Nearly 190,000 loyal donors

2010 Annual accounts

BALANCE SHEET

Assets in millions € 2010 2009 proforma* Liabilities in millions € 2010 2009 proforma*

Fixed assets 234.9 225.2 Shareholders' equity 256.9 259.2

Provisions for liabilities and charges 17.1 8.8

Dedicated funds 39.4 38.1

Inventory and other receivables 65.1 28.9 Other payables 95.2 72.1

Investments and cash equivalents 147.5 162.3 Debt 39.7 38.8

Accrued income and prepaid expenses

1.9 1.3Deferred income and accrued expenses

1.2 0.6

Total assets 449.5 417.7 Total liabilities 449.5 417.7

INCOME STATEMENT

In millions € 2010 2009 proforma*

Operating revenues for the fi nancial year 280.4 257.1

Net change in dedicated funds 2.6 2.1

Operating expenses, excluding commitments to be fulfi lled -278.9 -261

OPERATING INCOME -1.0 -1.8

Financial income received 4.0 4.0

Interest on borrowings -1.5 -1.1

Change in the provision on investment securities 0.1 6.9

NET FINANCIAL INCOME/(EXPENSE) 2.6 9.8

Gains or losses on asset disposals 1.0 1.0

Other exceptional income and expense -0.3 -0.3

NET EXCEPTIONAL INCOME/(LOSS) 0.7 0.7

NET INCOME 2.2 8,8

The 2010 annual accounts of Institut Curie have been certifi ed by auditors PricewaterhouseCoopers Audit.

* Including the René Huguenin Center.

Asset management

Intangible assetsInstitut Curie holds a brand name and patent portfolio that protect the products resulting from its expertise. These two assets are not capitalized in the balance sheet, but it is the policy of Institut Curie to protect them. The patents are exploited in the form of licensing agree-ments or joint ownership agreements established with manufacturers or biotechno-logy companies.

Real estate assetsInstitut Curie is the owner or occupant – at no charge or on a low-rent basis – of the buildings in which its treat-ment and research activities are practiced (Paris, Orsay, and Saint-Cloud). Several additional spaces are rented for provisional housing of tertiary activities.Institut Curie is also the owner, through a subsidiary, of a housing complex in Saint-Cloud. These premises are leased via a commercial lease.Institut Curie does not own any other investment properties.

Other tangible assetsInstitut Curie is the owner of all assets necessary for its activities, including heavy treatment and research equipment.Only a few pieces of offi ce equipment are rented or leased.

Financial assetsThe fi nancial assets of Institut Curie take the form of a securities portfolio that has been developed over the course of the institute’s existence.

These fi nancial assets are managed with the intent of perpetuating Institut Curie’s activities over the long term, while annually generating the resources needed by the institute for the fulfi llment of its public interest missions.

In keeping with this approach, Institut Curie takes great care to remain very prudent, systematically seeking broad diversifi cation in the nature of the fi nancial products and investment vehicles chosen.The Treasurer, with the assistance of the Finance

Committee, handles the portfolio’s strategic manage-ment. Medium- and long-term asset management has been entirely entrusted to outside service providers.Only cash management is handled in-house.

The year 2010 was marked by the Euro-zone sovereign debt crisis and by equity markets being further weakened by the crisis. In this volatile context, asset allocation management, investment diversifi cation, and better-than-anticipated performance on the part of the chosen portfolio mana-gers together achieved results that were 3.51%, higher than that of major markets (0.44 % for money markets; 2.18% for Euro-bonds; 2.67% for Euro shares).

A budget of more than €300m

40 Institut Curie — 2010 Annual Report

Glossary

Bioinformatics: Design and use of the tools needed for integration, analyze and archive the growing volume of biological and clinical data.

Cellular biology and developmental biology: Studying the “cell factory” to understand the tumor development process.

Cellular and molecular imaging: Exploring the cell’s most intimate details using the very latest image acquisition and processing techniques.

Epigenetics and genotoxicology: Studies of the cellular environment infl uencing gene expression and the study of genetic-lesion repair mechanisms caused by sun exposure, ionizing radiation, chemical products, etc.

Human genetics and oncogenesis: Identifying genome alterations and hereditary predispositions to certain tumors.

Immunology: Understanding and stimulating the immune system to stop the tumor’s progress.

Molecular mechanisms of oncogenesis: Understanding disruptions by studying the characteristics of cancer cells (instability, proliferation, invasive character).

Pharmacochemistry: Synthesizing molecules that specifi cally destroy cancer cells.

Physicochemistry of living systems: Studying complex assemblies of molecules involved in the major functions of living systems.

Radiotherapy: A set of treatments making use of the effects of radiation on biological tissue. Radiotherapy is part of the treatment plan for more than half of cancer patients. Radiotherapy takes the form of both external radiotherapy

(through the skin) and curietherapy (contact radiotherapy).

Immunotherapy: Biotherapy entailing stimulation of the immune system defenses. The goal is to fi ght cancer cells in the body by activating their specifi c destruction.

Hormone therapy: Treatment of certain hormone-dependent cancers (breast, prostate) using hormones. This makes it possible to limit the disease’s progress by blocking hormone production or actions, thereby limiting development of these kinds of tumors and inhibiting metastasis.

Chemotherapy: Using drugs to treat a disease through the blood. The molecules used in the treatment block cell division and reproduction and lead to the cell’s destruction. The latest chemotherapy molecules, developed through research and

biotechnology, have signifi cantly improved the outlook for cancer treatment.

Clinical trials: Clinical trials are a fi nal phase of multiple-stage research processes. Through rigorously applied methodologies, these trials determine the actual effectiveness – in a patient – of a new treatment protocol or molecule that has already been proven safe and active in early clinical trials.

Institut Curie Private foundation, granted charitable status in 1921 26 rue d’Ulm 75248 Paris cedex 05 — France Tel : + 33 (0)1 56 24 55 00

www.curie.fr/en

annuel report 2010

Documents

marie curie

research activities

annual reportinstitut

patient care activities

research contracts

fundamental research

activities growth

institut curies missions